Changchun BCHT Biotechnology Co.

Shanghai Stock Exchange 688276.SS

Changchun BCHT Biotechnology Co. Gross Profit Margin for the year ending December 31, 2023: 88.22%

Changchun BCHT Biotechnology Co. Gross Profit Margin is 88.22% for the year ending December 31, 2023, a 1.18% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Changchun BCHT Biotechnology Co. Gross Profit Margin for the year ending December 31, 2022 was 87.19%, a -1.24% change year over year.
Changchun BCHT Biotechnology Co. Gross Profit Margin for the year ending December 31, 2021 was 88.29%, a -0.03% change year over year.
Changchun BCHT Biotechnology Co. Gross Profit Margin for the year ending December 31, 2020 was 88.31%, a -2.28% change year over year.
Changchun BCHT Biotechnology Co. Gross Profit Margin for the year ending December 31, 2019 was 90.38%, a 1.61% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 688276.SS

Changchun BCHT Biotechnology Co.

CEO	Mr. Wei Kong
IPO Date	June 25, 2021
Location	China
Headquarters	1260 Huoju Road
Employees	1,241
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.

Key trends

Past 5 years